Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP

Antoni Bayes-Genis, Jaume Barallat, Amparo Galán, Marta De Antonio, Mar Domingo, Elisabet Zamora, Paloma Gastelurrutia, Joan Vila, Judith Peñafiel, Carolina Gálvez-Montón, Josep Lupón

Research output: Contribution to journalArticleResearchpeer-review

18 Citations (Scopus)

Abstract

© 2015 Sociedad Española de Cardiología. Introduction and objectives Neprilysin breaks down numerous vasoactive peptides. The soluble form of neprilysin, which was recently identified in heart failure, is associated with cardiovascular outcomes. Within a multibiomarker strategy, we directly compared soluble neprilysin and N-terminal pro-B-type natriuretic peptide as risk stratifiers in a real-life cohort of heart failure patients. Methods Soluble neprilysin, N-terminal pro-B-type natriuretic peptide, ST2, and high-sensitivity troponin T levels were measured in 797 consecutive ambulatory heart failure patients followed up for 4.7 years. Comprehensive multivariable analyses and soluble neprilysin vs N-terminal pro-B-type natriuretic peptide head-to-head assessments of performance were performed. A primary composite endpoint included cardiovascular death or heart failure hospitalization. A secondary endpoint explored cardiovascular death alone. Results Median soluble neprilysin and N-terminal pro-B-type natriuretic peptide concentrations were 0.64 ng/mL and 1187 ng/L, respectively. Both biomarkers significantly correlated with age (P <.001) and ST2 (P <.001), but only N-terminal pro-B-type natriuretic peptide significantly correlated with estimated glomerular filtration rate (P <.001), body mass index (P <.001), left ventricular ejection fraction (P =.02) and high-sensitivity troponin T (P <.001). In multivariable Cox regression analyses, soluble neprilysin remained independently associated with the composite endpoint (hazard ratio = 1.14; 95% confidence interval, 1.02-1.27; P =.03) and cardiovascular death (hazard ratio = 1.15; 95% confidence interval, 1.01-1.31; P =.04), but N-terminal pro-B-type natriuretic peptide did not. The head-to-head soluble neprilysin vs N-terminal pro-B-type natriuretic peptide comparison showed good calibration and similar discrimination and reclassification for both neurohormonal biomarkers, but only soluble neprilysin improved overall goodness-of-fit. Conclusions When added to a multimarker strategy, soluble neprilysin remained an independent prognosticator, while N-terminal pro-B-type natriuretic peptide lost significance as a risk stratifier in ambulatory patients with heart failure. Both biomarkers performed similarly in head-to-head analyses.
Original languageEnglish
Pages (from-to)1075-1084
JournalRevista Espanola de Cardiologia
Volume68
Issue number12
DOIs
Publication statusPublished - 1 Dec 2015

Keywords

  • failure
  • Heart
  • Neprilysin
  • NT-proBNP
  • Prognosis Survival

Fingerprint Dive into the research topics of 'Multimarker Strategy for Heart Failure Prognostication. Value of Neurohormonal Biomarkers: Neprilysin vs NT-proBNP'. Together they form a unique fingerprint.

Cite this